Molecular-Targeted Therapy of Pediatric Acute Myeloid Leukemia

Molecular-Targeted Therapy of Pediatric Acute Myeloid Leukemia

Acute myeloid leukemia (AML) accounts for approximately 15–20% of all childhood leukemia cases. The overall survival of children with acute myeloid leukemia does not exceed 82%, and the 5-year event-free survival rates range from 46% to 69%. Such suboptimal outcomes are the result of numerous mutati...

Full description

Bibliographic Details
Main Authors: Piotr Obszański, Anna Kozłowska, Jakub Wańcowiat, Julia Twardowska, Monika Lejman, Joanna Zawitkowska
Format: Article
Language:English
Published: MDPI AG 2022-06-01
Series:Molecules
Subjects:
acute myeloid leukemia
target therapies
pediatric AML
Online Access:https://www.mdpi.com/1420-3049/27/12/3911

Internet

https://www.mdpi.com/1420-3049/27/12/3911

Similar Items